UY33919A - Polimorfismos de un solo nucleótido en el promotor del gen VEGFA y su uso como marcadores predictivos para tratamientos anti-VEGF. - Google Patents

Polimorfismos de un solo nucleótido en el promotor del gen VEGFA y su uso como marcadores predictivos para tratamientos anti-VEGF.

Info

Publication number
UY33919A
UY33919A UY0001033919A UY33919A UY33919A UY 33919 A UY33919 A UY 33919A UY 0001033919 A UY0001033919 A UY 0001033919A UY 33919 A UY33919 A UY 33919A UY 33919 A UY33919 A UY 33919A
Authority
UY
Uruguay
Prior art keywords
single nucleotide
nucleotide polymorphisms
gene promoter
vegfa gene
predictive markers
Prior art date
Application number
UY0001033919A
Other languages
English (en)
Inventor
Chiron Blondel Marielle
Emmanuelle Cousin
Deleuze Jean-Francois
Jennifer Dreymann
Sandrine Mace
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33919A publication Critical patent/UY33919A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención se refiere al tratamiento y al diagnóstico de un grupo de pacientes que presentan alelos específicos de polimorfismos de un solo nucleótido en la región promotora del gen VEGFA. Estos pacientes responden mejor a Aflibercept y es más probable que sean tratados eficazmente con terapia anti-VEGF.
UY0001033919A 2011-02-23 2012-02-23 Polimorfismos de un solo nucleótido en el promotor del gen VEGFA y su uso como marcadores predictivos para tratamientos anti-VEGF. UY33919A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11305188 2011-02-23

Publications (1)

Publication Number Publication Date
UY33919A true UY33919A (es) 2012-09-28

Family

ID=44071008

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033919A UY33919A (es) 2011-02-23 2012-02-23 Polimorfismos de un solo nucleótido en el promotor del gen VEGFA y su uso como marcadores predictivos para tratamientos anti-VEGF.

Country Status (6)

Country Link
US (1) US20130330341A1 (es)
EP (1) EP2678441B1 (es)
AR (1) AR085301A1 (es)
AU (1) AU2012228544B2 (es)
UY (1) UY33919A (es)
WO (1) WO2012123227A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3012060A1 (en) * 2016-01-25 2017-08-03 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
RS51987B (en) * 2007-11-30 2012-02-29 Genentech Inc. VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIC THERAPY
US20120003641A1 (en) * 2008-11-05 2012-01-05 Graham Robert R Genetic polymorphisms in age-related macular degeneration
US20120100134A1 (en) * 2009-04-24 2012-04-26 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome

Also Published As

Publication number Publication date
AU2012228544B2 (en) 2015-06-11
US20130330341A1 (en) 2013-12-12
EP2678441A1 (en) 2014-01-01
EP2678441B1 (en) 2017-10-18
WO2012123227A1 (en) 2012-09-20
AR085301A1 (es) 2013-09-18
AU2012228544A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
UY33919A (es) Polimorfismos de un solo nucleótido en el promotor del gen VEGFA y su uso como marcadores predictivos para tratamientos anti-VEGF.
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
BR112013032605A2 (pt) variantes do promotor do gene gap codificador de glicerinaldeido-3-fosfato-de-hidrogenase
ECSP12012230A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
BR112013005872A2 (pt) compostos, composição farmacêutica e respectivos usos
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
EA201490052A1 (ru) Соединения, ингибирующие металлоферменты
EA201490038A1 (ru) Соединения, ингибирующие металлоферменты
EA201590747A1 (ru) Способы лечения с использованием аденовируса
BR112013020041A2 (pt) compostos e métodos para a modulação de quinases, e indicações para os mesmos
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
CO6660423A2 (es) Composiciones y métodos para tratar la enfermedad de gaucher
BR112013002655A2 (pt) novo tratamento de carcinoma de próstata
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
EA201500334A1 (ru) Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него
BR112014020233A2 (pt) seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
BR112012017483A2 (pt) previsão e redução de aloimunogenicidade de terapêuticos de proteína
MX2013013685A (es) Metodo para tratar articulos con dioxido de carbono.
BR112014000333A2 (pt) método de tratamento de aterosclerose em sujeitos com triglicerídeo alto
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
DK2740797T3 (da) Protein med aktivitet til at fremme fedtsyreforlængelse, derfor kodende gen samt anvendelse deraf

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019